John Dunlop is the Vice President of Neuroscience discovery research at Amgen based at the Kendall Square facility in Cambridge, MA, leading efforts focused on neurodegenerative disease, migraine and analgesia.
Previously he was VP and Head of the Neuroscience Innovative Medicine Unit at AstraZeneca leading discovery and early development efforts.
Prior to joining AstraZeneca, John was Executive Director in the Neuroscience Research Unit at Pfizer with responsibility for the preclinical portfolios in Neurology and Psychiatry; he joined Pfizer as part of the Wyeth integration and at Wyeth held roles as head of Psychiatry and Acting head of Neuroscience.
Trained as a neuropharmacologist, John’s current research interests include the role of proteostasis mechanisms, innate immunity and mitochondrial dysfunction in neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and ALS, and on the emerging genetics of brain disorders.
John is a member of the Executive Scientific Advisory Board for the Michael J Fox Foundation for Parkinson’s disease, a board member of Target ALS, and serves as a scientific advisor to the ALS Association, the frontotemporal dementia biomarkers SAB, the Weston Brain Institute of Canada, and the National Institute for Neurological Disorders and Stroke for translational programs in neurological disorders.